DK1897552T3 - Polymer-konjugeret glycosyleret neublastin - Google Patents

Polymer-konjugeret glycosyleret neublastin

Info

Publication number
DK1897552T3
DK1897552T3 DK07012662T DK07012662T DK1897552T3 DK 1897552 T3 DK1897552 T3 DK 1897552T3 DK 07012662 T DK07012662 T DK 07012662T DK 07012662 T DK07012662 T DK 07012662T DK 1897552 T3 DK1897552 T3 DK 1897552T3
Authority
DK
Denmark
Prior art keywords
neublastin
conjugated
polypeptides
polymer
terminus
Prior art date
Application number
DK07012662T
Other languages
Danish (da)
English (en)
Inventor
Dinah Wen-Yee Sah
Blake R Pepinsky
Anthony Rossomando
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33310837&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1897552(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK1897552T3 publication Critical patent/DK1897552T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK07012662T 2003-04-18 2004-04-16 Polymer-konjugeret glycosyleret neublastin DK1897552T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46389903P 2003-04-18 2003-04-18
PCT/US2004/011745 WO2004094592A2 (en) 2003-04-18 2004-04-16 Polymer-conjugated glycosylated neublastin

Publications (1)

Publication Number Publication Date
DK1897552T3 true DK1897552T3 (da) 2009-10-05

Family

ID=33310837

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07012662T DK1897552T3 (da) 2003-04-18 2004-04-16 Polymer-konjugeret glycosyleret neublastin

Country Status (11)

Country Link
US (2) US8163875B2 (https=)
EP (3) EP1897552B1 (https=)
JP (2) JP4742030B2 (https=)
AT (1) ATE433759T1 (https=)
AU (1) AU2004233079B2 (https=)
CA (2) CA2864810A1 (https=)
DE (1) DE602004021648D1 (https=)
DK (1) DK1897552T3 (https=)
ES (2) ES2328640T3 (https=)
NZ (2) NZ543365A (https=)
WO (1) WO2004094592A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2783310B2 (ja) 1993-01-28 1998-08-06 トヨタ車体株式会社 エンボス成形方法
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US20040077543A1 (en) * 2001-03-28 2004-04-22 Sah Dinah W. Y. Treatment using neublastin polypeptides
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
NZ581460A (en) * 2003-01-31 2010-02-26 Biogen Idec Inc Polymer conjugates of mutated neublastin
CA2864810A1 (en) 2003-04-18 2004-11-04 Biogen Idec Ma, Inc. Polymer-conjugated glycosylated neublastin
RU2005138368A (ru) 2003-06-10 2006-07-27 ЭнЭсДЖЕНЕ А/С (DK) Улучшенная секреция нейбластина
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
BRPI0514534A (pt) * 2004-08-19 2008-06-17 Biogen Idec Inc variantes de neublastina
NZ553420A (en) 2004-08-19 2010-02-26 Biogen Idec Inc Refolding transforming growth factor beta family proteins
WO2007042040A2 (en) * 2005-10-11 2007-04-19 Ns Gene A/S TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
EP1993590B1 (en) * 2006-03-01 2013-12-25 Biogen Idec MA Inc. Compostions and methods for administering gdnf ligand family proteins
JP5583005B2 (ja) 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管新生を増大させるための組成物および方法
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
US10317376B2 (en) 2012-04-11 2019-06-11 Bioverativ Therapeutics Inc. Methods of detecting glycosaminoglycans

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
HU187037B (en) 1983-04-19 1985-10-28 Tibor Sinko Rope-stretching device
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
CA2109085C (en) 1991-04-25 2003-03-11 Keith E. Dionne Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
WO1993000951A1 (en) 1991-07-02 1993-01-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
MX9205293A (es) 1991-09-20 1993-05-01 Syntex Sinergen Neuroscience J Factores neurotrofico derivado del glial
US5939524A (en) 1991-12-09 1999-08-17 The Scripps Research Institute Platelet GPIII P1A1 and P1A2 epitopes, their preparation and use
US5414135A (en) 1991-12-30 1995-05-09 Sterling Winthrop Inc. Vinyl sulfone coupling of polyoxyalkylenes to proteins
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
ES2179831T3 (es) 1992-09-29 2003-02-01 Inhale Therapeutic Syst Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana.
US5349056A (en) 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
CA2092271C (en) 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
ATE218893T1 (de) 1993-08-12 2002-06-15 Neurotech Sa Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten
DE4339605A1 (de) 1993-11-20 1995-05-24 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden
US5834029A (en) 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5770577A (en) 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5733729A (en) 1995-09-14 1998-03-31 Affymetrix, Inc. Computer-aided probability base calling for arrays of nucleic acid probes on chips
US5641749A (en) 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US6063757A (en) 1995-11-29 2000-05-16 Urso; Richard G. Wound treatment method with nerve growth factor
US6084076A (en) 1995-12-21 2000-07-04 Ajinomoto Co., Inc. Method of refolding human activin A
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
US5754524A (en) 1996-08-30 1998-05-19 Wark; Barry J. Computerized method and system for analysis of an electrophoresis gel test
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
AU736670B2 (en) 1996-09-26 2001-08-02 Medical Research Council Chaperone fragments
KR100195886B1 (ko) 1996-11-01 1999-06-15 김상조 당뇨병 치료용 의약조성물
GB9718908D0 (en) * 1997-09-05 1997-11-12 Rowett Research Services Limit Proteins
US6653098B1 (en) 1998-02-23 2003-11-25 G. D. Searle & Co. Method of producing mouse and human endostatin
US20020055467A1 (en) 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US7067473B1 (en) 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
WO2000004050A2 (en) 1998-07-14 2000-01-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
CA2344277A1 (en) 1998-09-22 2000-03-30 University Of Maryland, Baltimore Cystine knot growth factor mutants
US20020002269A1 (en) * 1998-09-29 2002-01-03 Jeffrey D. Milbrandt Artemin, a neurotrophic factor
US6361771B1 (en) 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
JP2003525916A (ja) 1999-04-22 2003-09-02 エイドゲントシッシュ テクニーシェ ホッシュール チューリッヒ モディファイドタンパク質マトリクス
WO2001030375A2 (en) 1999-10-29 2001-05-03 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Use of gdnf for treating corneal defects
CA2327208A1 (en) 2000-11-30 2002-05-30 The Government Of The United States Of America Methods of increasing distribution of therapeutic agents
IL140110A0 (en) * 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
BR0116749A (pt) 2000-12-22 2006-11-28 Genentech Inc usos de artemina ou seu agonista e artigo manufaturado
UA82983C2 (ru) 2001-02-01 2008-06-10 Байоджен Айдек Ма Інк. Полимерные коньюгаты найбластина и способы их использования
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
EP1395279B1 (en) * 2001-03-28 2011-10-05 Biogen Idec MA Inc. Use of neublastin polypeptides for treating neuropathic pain
US20040077543A1 (en) 2001-03-28 2004-04-22 Sah Dinah W. Y. Treatment using neublastin polypeptides
ATE546146T1 (de) 2001-04-24 2012-03-15 Purdue Research Foundation Verfahren und zusammensetzungen zur behandlung von nervengewebeverletzungen in säugetieren
US7164007B2 (en) 2001-06-20 2007-01-16 Genentech, Inc. Anti-PR020044 antibodies
US20040028613A1 (en) 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
US7129085B2 (en) 2001-10-11 2006-10-31 Bristol-Myers Squibb Company Polynucleotides encoding a human leucine-rich repeat domain containing protein, HLLRCR-1
GB0205022D0 (en) 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
JP4310608B2 (ja) 2002-04-25 2009-08-12 東洋紡績株式会社 Ｈｓｐ７０ファミリータンパク質基質結合ドメインフラグメントの利用方法
CA2864810A1 (en) 2003-04-18 2004-11-04 Biogen Idec Ma, Inc. Polymer-conjugated glycosylated neublastin
RU2005138368A (ru) 2003-06-10 2006-07-27 ЭнЭсДЖЕНЕ А/С (DK) Улучшенная секреция нейбластина
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
US20050180957A1 (en) 2004-01-16 2005-08-18 Scharp David W. Method of using fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells
KR100917403B1 (ko) 2004-06-23 2009-09-14 티슈진, 인코포레이티드 신경 재생
US7598356B2 (en) 2004-07-08 2009-10-06 Board of Regents of the University of Nebraska by and on behalf of the University of Nebraska Medical Center Method for purifying a protein of the cystine-knot superfamily
BRPI0514534A (pt) 2004-08-19 2008-06-17 Biogen Idec Inc variantes de neublastina
NZ553420A (en) 2004-08-19 2010-02-26 Biogen Idec Inc Refolding transforming growth factor beta family proteins
WO2007042040A2 (en) 2005-10-11 2007-04-19 Ns Gene A/S TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
EP1993590B1 (en) 2006-03-01 2013-12-25 Biogen Idec MA Inc. Compostions and methods for administering gdnf ligand family proteins
WO2007127803A2 (en) 2006-04-25 2007-11-08 The Regents Of The University Of California Administration of growth factors for the treatment of cns disorders
JP5583005B2 (ja) 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管新生を増大させるための組成物および方法

Also Published As

Publication number Publication date
ES2479942T3 (es) 2014-07-25
US8642732B2 (en) 2014-02-04
AU2004233079B2 (en) 2009-09-17
CA2864810A1 (en) 2004-11-04
DE602004021648D1 (de) 2009-07-30
JP4742030B2 (ja) 2011-08-10
NZ543365A (en) 2009-02-28
CA2522364A1 (en) 2004-11-04
US20070238650A1 (en) 2007-10-11
WO2004094592A3 (en) 2006-04-27
CA2522364C (en) 2014-12-09
EP2322205A1 (en) 2011-05-18
US20120316109A1 (en) 2012-12-13
JP5415392B2 (ja) 2014-02-12
NZ574121A (en) 2011-06-30
ES2328640T3 (es) 2009-11-16
EP1618179B1 (en) 2014-05-07
EP1618179A2 (en) 2006-01-25
EP1618179A4 (en) 2008-03-05
ATE433759T1 (de) 2009-07-15
US8163875B2 (en) 2012-04-24
JP2011084567A (ja) 2011-04-28
JP2006523709A (ja) 2006-10-19
EP1897552B1 (en) 2009-06-17
AU2004233079A1 (en) 2004-11-04
WO2004094592A2 (en) 2004-11-04
EP1897552A1 (en) 2008-03-12

Similar Documents

Publication Publication Date Title
DK1897552T3 (da) Polymer-konjugeret glycosyleret neublastin
EP2298331A3 (en) Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
NO2017027I2 (no) efmoroctocog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
PT1288223E (pt) Derivados de peptidos terapeuticos
WO2002010195A3 (en) Modified peptides with increased potency
WO2002002597A3 (en) Peptide extended glycosylated polypeptides
CA2155185A1 (en) Totally synthetic affinity reagents
MXPA03007563A (es) Recuperacion incrementada de proteinas activas.
BRPI0417916A (pt) proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
EP0695171A1 (en) GONADOTROPINE CONTAINING FREEZER DRIED DROPS
WO2004069176A3 (en) Polymer conjugates of mutated neublastin
IL227752A0 (en) Polymer conjugates of modified neoblastin
CA2077590A1 (en) Recombinant dna coding for a protein with endochitinase activity
DE60231157D1 (de) Crfr1 selektive liganden
EA200001252A1 (ru) КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА